Terms: = Prostate cancer AND BRIP1, MGC126521, 83990, ENSG00000136492, FANCJ, FLJ90232, Q9BX63, MGC126523, OF AND Treatment
744 results:
1. Active surveillance of low-grade prostate cancer using the SurACaP Criteria: A multi-institutional series with a median follow-up of 10years.
Leclercq L; Bastide C; Lechevallier E; Walz J; Charvet AL; Gondran-Tellier B; Campagna J; Savoie PH; Long-Depaquit T; Daniel L; Rossi D; Pignot G; Baboudjian M
Fr J Urol; 2024 Mar; 34(2):102571. PubMed ID: 38717459
[TBL] [Abstract] [Full Text] [Related]
2. Revealing the mechanism of ethyl acetate extracts of Semen Impatientis against prostate cancer based on network pharmacology and transcriptomics.
Hu B; Wang C; Wu Y; Han C; Liu J; Chen R; Wang T
J Ethnopharmacol; 2024 Aug; 330():118228. PubMed ID: 38643863
[TBL] [Abstract] [Full Text] [Related]
3. Current Systemic Therapy in Men with Metastatic Castration-Sensitive prostate cancer.
Grisay G; Lavaud P; Fizazi K
Curr Oncol Rep; 2024 May; 26(5):488-495. PubMed ID: 38592590
[TBL] [Abstract] [Full Text] [Related]
4. Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology.
Kango G; Malek R; Mannuel H; Hussain A
Curr Opin Oncol; 2024 May; 36(3):195-201. PubMed ID: 38573209
[TBL] [Abstract] [Full Text] [Related]
5. Highlighting recent progress in the treatment of men with advanced prostate cancer.
Gourdin T
Curr Opin Oncol; 2024 May; 36(3):174-179. PubMed ID: 38573207
[TBL] [Abstract] [Full Text] [Related]
6. A metabolomics approach reveals metabolic disturbance of human cholangiocarcinoma cells after parthenolide treatment.
He Y; Yu Q; Ma X; Lv D; Wang H; Qiu W; Chen XF; Jiao Y; Liu Y
J Ethnopharmacol; 2024 Jun; 328():118075. PubMed ID: 38513779
[TBL] [Abstract] [Full Text] [Related]
7. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive prostate cancer Demonstrating "BRCAness" Genotype (ROAR).
Sahu KK; Li H; Mathew Thomas V; Benson M; Boucher K; Gupta S; Kohli M; Swami U; Agarwal N; Maughan BL
Oncologist; 2024 May; 29(5):450-e725. PubMed ID: 38452035
[TBL] [Abstract] [Full Text] [Related]
8. Optimal systemic therapy in men with low-volume prostate cancer.
Saxena A; Andrews J; Bryce AH; Riaz IB
Curr Opin Urol; 2024 May; 34(3):183-197. PubMed ID: 38445371
[TBL] [Abstract] [Full Text] [Related]
9. Metastasis-directed therapy in oligometastatic prostate cancer.
Miszczyk M; Soeterik T; Marra G; Matsukawa A; Shariat SF
Curr Opin Urol; 2024 May; 34(3):178-182. PubMed ID: 38426229
[TBL] [Abstract] [Full Text] [Related]
10. treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract] [Full Text] [Related]
11. Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo.
Paindelli C; Parietti V; Barrios S; Shepherd P; Pan T; Wang WL; Satcher RL; Logothetis CJ; Navone N; Campbell MT; Mikos AG; Dondossola E
Acta Biomater; 2024 Apr; 178():83-92. PubMed ID: 38387748
[TBL] [Abstract] [Full Text] [Related]
12. CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression.
Chen H; Dong K; Ding J; Xia J; Qu F; Lan F; Liao H; Qian Y; Huang J; Xu Z; Gu Z; Shi B; Yu M; Cui X; Yu Y
Cancer Lett; 2024 Apr; 587():216725. PubMed ID: 38364963
[TBL] [Abstract] [Full Text] [Related]
13. Stereotactic ablative radiation therapy in metastatic prostate cancer.
Bazyar S; Mannuel H; Tran PT
Curr Opin Oncol; 2024 May; 36(3):180-185. PubMed ID: 38362949
[TBL] [Abstract] [Full Text] [Related]
14. Current evidence on local therapy in oligometastatic prostate cancer.
Basourakos SP; Henning G; Karnes RJ
Curr Opin Urol; 2024 May; 34(3):198-203. PubMed ID: 38305293
[TBL] [Abstract] [Full Text] [Related]
15. Germline Mutations and Ancestry in prostate cancer.
Bataba E; Babcock K; Isensee KA; Eldhose B; Kohaar I; Chesnut GT; Dobi A
Curr Oncol Rep; 2024 Feb; 26(2):175-180. PubMed ID: 38265515
[TBL] [Abstract] [Full Text] [Related]
16. Stereotactic body radiotherapy (SIB-VMAT technique) to dominant intraprostatic lesion (DIL) for localized prostate cancer: a dose-escalation trial (DESTROY-4).
Deodato F; Ferro M; Bonome P; Pezzulla D; Romano C; Buwenge M; Cilla S; Morganti AG; Macchia G
Strahlenther Onkol; 2024 Mar; 200(3):239-249. PubMed ID: 38180492
[TBL] [Abstract] [Full Text] [Related]
17. cancer survivor late-effects, chronic health problems after cancer treatment: what's the evidence from population and registry data and where are the gaps?
Faithfull S; Greenfield D
Curr Opin Support Palliat Care; 2024 Mar; 18(1):55-64. PubMed ID: 38170192
[TBL] [Abstract] [Full Text] [Related]
18. prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Chowdhury S; Bjartell A; Agarwal N; Chung BH; Given RW; Pereira de Santana Gomes AJ; Merseburger AS; Özgüroğlu M; Soto ÁJ; Uemura H; Ye DW; Brookman-May SD; Londhe A; Bhaumik A; Mundle SD; Larsen JS; McCarthy SA; Chi KN
Future Oncol; 2024 Mar; 20(10):563-578. PubMed ID: 38126311
[TBL] [Abstract] [Full Text] [Related]
19. Assessment of prostate and Bladder cancer Genomic Biomarkers Using Artificial Intelligence: a Systematic Review.
Bazarkin A; Morozov A; Androsov A; Fajkovic H; Rivas JG; Singla N; Koroleva S; Teoh JY; Zvyagin AV; Shariat SF; Somani B; Enikeev D
Curr Urol Rep; 2024 Jan; 25(1):19-35. PubMed ID: 38099997
[TBL] [Abstract] [Full Text] [Related]
20. AI-powered radiomics: revolutionizing detection of urologic malignancies.
Gelikman DG; Rais-Bahrami S; Pinto PA; Turkbey B
Curr Opin Urol; 2024 Jan; 34(1):1-7. PubMed ID: 37909882
[TBL] [Abstract] [Full Text] [Related]
[Next]
